Blood cancers

Novel agents bring more choice to RRMM treatment

Sponsored by Janssen-Cilag Pty Ltd

Development of novel agents and advances in the understanding of the disease biology have improved treatment options for patients with Relapsed Refractory Multiple Myeloma, with tailored therapy now considered the optimal approach. In this podcast, Doctor Saad Usmani gives his perspectives on managing relapsed refractory disease in this new era of treatment choice. This podcast ...

Already a member?

Login to keep reading.

© 2021 the limbic